Driving innovation in precision medicine through translational life sciences research at the University of Leicester

Lead Research Organisation: University of Leicester

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description BHF Accelerator Early Career researcher Fund - Myocardial Scar project
Amount £56,413 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Cardiac rest and stress metabolism in patients with Type 2 Diabetes
Amount £136,122 (GBP)
Funding ID FS/18/26/33501 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 10/2020
 
Description Clinical Research Network East Midlands - Myocardial Scar project
Amount £5,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description Development grant - NEK project
Amount £10,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Fellowship - Diagnostics of Lyme disease
Amount £97,932 (GBP)
Organisation Phelix Research & Development 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2020
 
Description Heart failure in type 2 diabetes: improving diagnosis and management in a multi-ethnic population.
Amount £1,950,000 (GBP)
Funding ID RP-2017-08-ST2-007 
Organisation National Institute of Health Research and Development (NIHRD) 
Sector Public
Country Indonesia
Start  
 
Description IMPACT Doctoral Training Partnership Award - Brain TV
Amount £60,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description International PhD student
Amount £90,000 (GBP)
Organisation Government of Saudi Arabia 
Sector Public
Country Saudi Arabia
Start  
 
Description LPMI Capacity Building Call - (Predictive breath volatile signatures - severe asthma)
Amount £55,000 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start  
 
Description LPMI Capacity Building Call - Leicester Molecular Diagnostics (LMD)
Amount £60,000 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS) - LifeMap
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2019 
 
Description NIHR academic fundation trainee - Paediatric Ophthalmology
Amount £31,107 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description Prevalence and determinants of subclinical cardiovascular dysfunction in adults with Type 2 Diabetes Mellitus
Amount £275,156 (GBP)
Funding ID FS/16/47/32190 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 07/2020
 
Description UK Consortium for MetAbolic Phenotyping (MAP UK)
Amount £154,752 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description iCase student funded through LifeArc - Sin3A project
Amount £26,000 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
 
Title Software development for the analysis of neural recordings obtained from patients implanted with electrodes for clinical reasons 
Description Software development for the analysis of neural recordings obtained from patients implanted with electrodes for clinical reasons 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2018 
Provided To Others? Yes  
Impact It is too early to evaluate the impact of the new tool 
 
Title Targeting Proline biosynthesis for cancer therapy - enzymatic assay 
Description An enzyme assay was established as a tool to screen fragments generated from other screening methods, such as NMR. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Screening has recently begun, therefore no impact can be reported at this moment in time. 
 
Title Application of Artificial Intelligence in Paediatric Ophthalmology - a pilot study 
Description A database of paediatric optical coherence tomography (OCT) scans which contains images of children retinas. The database contains scans from normal controls and children with retinal abnormalities.The project is supporting full annotation of the scans. In the process of seeking FDA approval as a validation set for new OCT hard- and software. 
Type Of Material Computer model/algorithm 
Year Produced 2018 
Provided To Others? No  
Impact The database under development will facilitate a multi-end point searchable database to be used as a learning and test data sets for the developed algorithm. Outputs will aim to provide earlier detection of retinal abnormalities and the earlier diagnosis of genetic disease leading to differential treatment outcomes and better prognosis for a range of eye and other physiological abnormalities with genetic components. 
 
Title Using AI to Automatically Detect and Quantify Myocardial Scar 
Description Fully annotated series of cardiac MRI (CMR) images with varying states of cardiac fat deposition in patients with and without type 2 diabetes. Will utilise existing CMR resources and computing expertise to develop a fully automated scar detection using machine learning algorithm. 
Type Of Material Computer model/algorithm 
Year Produced 2018 
Provided To Others? No  
Impact No impact to date. The project is ongoing and is sufficient to provide both learning and test datasets for the development of a new algorithm for detecting patients 'at high risk' of heart failure. 
 
Description Application of Artificial Intelligence in Paediatric Ophthalmology - a pilot study 
Organisation Leica Microsystems GmbH
Country Germany 
Sector Private 
PI Contribution The research team at Leicester is at the forefront of paediatric OCT imaging and have previously published seminal papers in the field. One of our landmark papers is on the classification of retinal development disorders (foveal hypoplasia) which allows clinicians to grade, diagnose and provide prognosis for children with arrested retinal development. Gave access to the largest reference dataset for paediatric OCTs worldwide.
Collaborator Contribution MTA signed in 2019 to allow Leica to share the code for their software. This will allow direct access to the encrypted images from the scans so it could be used for the AI system (training, optimization and validation). This would also allow batch processing and thus scaling up the dataset further. Leica are interested in further collaboration, but are awaiting data from the PI, which is expected in July 2020.
Impact 3x 1 year NIHR academic foundation trainee posts - to perform segmentation of scans and developing AI-based technique for segmentation. NIHR Academic clinical fellowship. Scoping with industrial partners (e.g. Translational Imaging Innovations). Gave confidence for follow-on funding (MC_PC_18054).
Start Year 2019
 
Description Application of a phage-PCR based technology to develop novel diagnostic tools for Tuberculosis 
Organisation Luminex Corporation
Department Luminex (Canada)
Country Canada 
Sector Private 
PI Contribution The capability to conduct a prospective cohort study with TB and non-TB patients. Provide access to patient samples and identify eligible samples for recruitment.
Collaborator Contribution Collaborators in Nottingham hold the I.P. for the assay methodology used which has been licenced to the SME biotechnology company, PBD Biotech Ltd (who are partly owned by University of Nottingham). PBD Biotech have agreed to cover the labour costs of performing the tests (In-kind contribution). Luminex contribution: will place a proprietary platform for developmental work at UoL and UoN and provide support for platform adaptation (in-kind value unknown). Oxford Immunotec are contributing expertise and equipment to enable automation of the assay- by automating the separation of lymphocytes from whole blood.
Impact None to date. (Reviewed March 2021 - Updated march 2021)
Start Year 2019
 
Description Application of a phage-PCR based technology to develop novel diagnostic tools for Tuberculosis 
Organisation Oxford Immunotec Global
Country United Kingdom 
Sector Private 
PI Contribution The capability to conduct a prospective cohort study with TB and non-TB patients. Provide access to patient samples and identify eligible samples for recruitment.
Collaborator Contribution Collaborators in Nottingham hold the I.P. for the assay methodology used which has been licenced to the SME biotechnology company, PBD Biotech Ltd (who are partly owned by University of Nottingham). PBD Biotech have agreed to cover the labour costs of performing the tests (In-kind contribution). Luminex contribution: will place a proprietary platform for developmental work at UoL and UoN and provide support for platform adaptation (in-kind value unknown). Oxford Immunotec are contributing expertise and equipment to enable automation of the assay- by automating the separation of lymphocytes from whole blood.
Impact None to date. (Reviewed March 2021 - Updated march 2021)
Start Year 2019
 
Description Brain TV - LD3 project: exchange with Nihon Kohden (Japan) 
Organisation Nihon Kohden (Japan)
Country Japan 
Sector Private 
PI Contribution Software and device development. Documentation for regulatory approvals. Healthy volunteer and clinical data gathering.
Collaborator Contribution Providing dedicated engineering support for device development and commercialisation, equipment and financial support and support for our pathway to impact.
Impact Through IAX industry exchange awards we were able to present plans for a further multicentre proposal to Nihon Kohden in July 2019. As part of our visit, NK agreed to provide a letter of support for external funding applications. The letter of support will include equipment loan of new prototype devices, provision of clinical consumables, as well as a more accurate estimate of their in kind support for the duration of the project, plus a direct financial contribution to cover NHS and regulatory costs associated with multi-centre research. Further funding: linked to MRC CiC MC_PC_17171 Patent number: 20150359448, 1x publication: DOI:1742271X19894601, 1x publication submitted, 2x publications to be completed for submission, 2x publications in preparation. Conference presentations: 1x Oral and three poster presentations at Brain 2019 in Yokohama, Japan (July 4th-7th 2019), 1x Oral presentation at the International Health Technology and Management Congress (Rome, October 21st-22nd, 2019), 1x Poster presentation at the London Trauma Conference, London, UK, 10-13th December 2019. An abstract and accompanying article has been submitted to the 28th Mediterranean Conference on Control and Automation (MED'2020) to be held in Nice, 16th-19th June 2020. The MRC DTP studentship worth £85,000 and ongoing collaboration. (Reviewed March 2021- Updated march 2021)
Start Year 2019
 
Description Brain TV confidence in concept: severe brain injury 
Organisation Nihon Kohden (Japan)
Country Japan 
Sector Private 
PI Contribution Applying for MRHA approval to test device. Healthy volunteer and clinical data gathering. Database of pathological brain tissue motion recordings.
Collaborator Contribution Providing dedicated engineering support for hardware and device development and commercialisation. Equipment loan and financial support for consumables.
Impact 1/ Study outcome: the study succeeded in testing the Brain TV system clinically by obtaining brain pulsation measurements and clinical outcome data from a total of 44 patients with suspected brain injury recruited from the Leicester Royal Infirmary Emergency Department. The majority of patients had no major brain injury, and were correctly excluded by Brain TV, with the exception of one patient with a 5 mm mid-line shift whose brain tissue pulsations were correctly identified by Brain TV as abnormal. This case was presented as a poster at the London Trauma conference in December 2019. 2/ Further funding: linked to P2D funded exchange programme funded under MRC_PC_17194 which supported a visit for face-to-face meetings with Nihon Kohden. Through this industry exchange award, we were able to present plans for a further multicentre proposal to Nihon Kohden in July 2019. As part of our visit, NK agreed to provide a letter of support for external funding applications. The letter of support included equipment loan of new prototype devices, provision of clinical consumables, as well as a more accurate estimate of their in kind support for the duration of the project, plus a direct financial contribution to cover NHS and regulatory costs associated with multi-centre research. 3/ Multidisciplinary between UHL Medical Physics and Clinical Engineering, UoL Cardiovascular Sciences and UoL Engineering. 4/ Patent number: 20150359448, 5/ Publications: 1x publication: DOI:1742271X19894601, 1x publication submitted, 2x publications to be completed for submission, 2x publications in preparation. 6/ Conference presentations: 1x Oral and three poster presentations at Brain 2019 in Yokohama, Japan (July 4th-7th 2019), 1x Oral presentation at the International Health Technology and Management Congress (Rome, October 21st-22nd, 2019), 1x Poster presentation at the London Trauma Conference, London, UK, 10-13th December 2019. An abstract and accompanying article has been submitted to the 28th Mediterranean Conference on Control and Automation (MED'2020) to be held in Nice, 16th-19th June 2020.
Start Year 2018
 
Description Breath sampler for clinical diagnostics and stratified medicine 
Organisation Loughborough University
Country United Kingdom 
Sector Academic/University 
PI Contribution The research team are able to utilise the knowledge and expertise of clinicians and academics within the EMBER consortium - focused on Mass Spectrometer analysis of volatile compounds found in breath. The research team also provide access to patients and patient samples with a broad range of respiratory conditions.
Collaborator Contribution Renfrew Group International (RGi) are an award winning design consultancy company, who provide specific know-how and expertise for innovative product design. RGi have provided design services, electronics manufacturing and rapid prototyping facilities to enable the production of a novel breath collection system. Loughborough University provide access to Mass Spectrometer expertise and equipment complimentary to the expertise in breath analysis at Leicester.
Impact University of Leicester and Renfrew Group engaged in a series of meetings and staff placements (supported by P2D) to establish the feasibility and potential scope of use for a robust novel breath collection system that would provide the ability to offer disposable (sterile) patient contact surfaces, multi channel collection and applicability to normal clinical practice. University of Loughborough, University of Loughborough and Renfrew Group have now produced 3 prototype devices ready to test in a clinical setting. In the process of the project University of Loughborough have contributed £70,000 in funding to the prototype development The project has also benefited from the placement of one of the academic leads into the iCURE commercialisation training programme (estimated £50,000 in-kind contribution) to promote commercial development of the new collection system. The project is in the process of being 'pitched' to a panel of investors through Innovate UK (March 2021) and Mercia Venture Fund (April 2021). (reviewed March 2021 - updated March 2021)
Start Year 2019
 
Description Breath sampler for clinical diagnostics and stratified medicine 
Organisation Renfrew Group International
Country United Kingdom 
Sector Private 
PI Contribution The research team are able to utilise the knowledge and expertise of clinicians and academics within the EMBER consortium - focused on Mass Spectrometer analysis of volatile compounds found in breath. The research team also provide access to patients and patient samples with a broad range of respiratory conditions.
Collaborator Contribution Renfrew Group International (RGi) are an award winning design consultancy company, who provide specific know-how and expertise for innovative product design. RGi have provided design services, electronics manufacturing and rapid prototyping facilities to enable the production of a novel breath collection system. Loughborough University provide access to Mass Spectrometer expertise and equipment complimentary to the expertise in breath analysis at Leicester.
Impact University of Leicester and Renfrew Group engaged in a series of meetings and staff placements (supported by P2D) to establish the feasibility and potential scope of use for a robust novel breath collection system that would provide the ability to offer disposable (sterile) patient contact surfaces, multi channel collection and applicability to normal clinical practice. University of Loughborough, University of Loughborough and Renfrew Group have now produced 3 prototype devices ready to test in a clinical setting. In the process of the project University of Loughborough have contributed £70,000 in funding to the prototype development The project has also benefited from the placement of one of the academic leads into the iCURE commercialisation training programme (estimated £50,000 in-kind contribution) to promote commercial development of the new collection system. The project is in the process of being 'pitched' to a panel of investors through Innovate UK (March 2021) and Mercia Venture Fund (April 2021). (reviewed March 2021 - updated March 2021)
Start Year 2019
 
Description Cardio Health MRI Scan 
Organisation Resonance Health
Country Australia 
Sector Private 
PI Contribution The patient recruitment and MRI imaging has taken place at Leicester. A proof of concept study adapting Resonance Health's existing algorithm with cardiac gating and acquired images from healthy volunteers and cardiology patients has been completed - with input from both partners.
Collaborator Contribution Resonance Health have developed the algorithm for cardio MRI imaging and will help with analysing the MRI scans.
Impact P2D funding (2016/2017 MC_PC_15056) was awarded to the PI to visit Resonance Health in Perth Australia, and for physicists from Resonance Health to come to Leicester to optimise the MRI sequence. Healthy volunteers and patients have been scanned and analysis of images is underway. Full patient and volunteer recruitment is complete and data analysis is under way with Resonance Health. A publication in a high profile journal is expected in 2021 (delayed due to COVID increased clinical commitments). It is anticipated that the data will inform future imaging diagnostics proposals and will have positive impact on patients to help early disease management for patients susceptible to severe cardiac disease. Updated February 2021.
Start Year 2017
 
Description Development and evaluation of predictive breath volatile signatures of early treatment response/failure in a subset (T2HIGH) of severe asthmatics 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Expertise in breathomics - volatile organic compound detection in breath (The East Midlands Breathomics Pathology Node - EMBER) Access to patients via clinical trials, sample processing and clinical data to assess the efficacy of novel compounds on disease control
Collaborator Contribution Access to novel therapeutic agents Funds to support clinical trials and to pay for access to clinical research data sets. Contributed to a value of up to £400,000.
Impact Activity and access to samples is part of ongoing discussion with the EMBER commercail consortia and the University Hospitals of Leicester
Start Year 2018
 
Description Development and evaluation of predictive breath volatile signatures of early treatment response/failure in a subset (T2HIGH) of severe asthmatics 
Organisation Chiesi
Country Italy 
Sector Private 
PI Contribution Expertise in breathomics - volatile organic compound detection in breath (The East Midlands Breathomics Pathology Node - EMBER) Access to patients via clinical trials, sample processing and clinical data to assess the efficacy of novel compounds on disease control
Collaborator Contribution Access to novel therapeutic agents Funds to support clinical trials and to pay for access to clinical research data sets. Contributed to a value of up to £400,000.
Impact Activity and access to samples is part of ongoing discussion with the EMBER commercail consortia and the University Hospitals of Leicester
Start Year 2018
 
Description Development and evaluation of predictive breath volatile signatures of early treatment response/failure in a subset (T2HIGH) of severe asthmatics 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Expertise in breathomics - volatile organic compound detection in breath (The East Midlands Breathomics Pathology Node - EMBER) Access to patients via clinical trials, sample processing and clinical data to assess the efficacy of novel compounds on disease control
Collaborator Contribution Access to novel therapeutic agents Funds to support clinical trials and to pay for access to clinical research data sets. Contributed to a value of up to £400,000.
Impact Activity and access to samples is part of ongoing discussion with the EMBER commercail consortia and the University Hospitals of Leicester
Start Year 2018
 
Description Development and evaluation of predictive breath volatile signatures of early treatment response/failure in a subset (T2HIGH) of severe asthmatics 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution Expertise in breathomics - volatile organic compound detection in breath (The East Midlands Breathomics Pathology Node - EMBER) Access to patients via clinical trials, sample processing and clinical data to assess the efficacy of novel compounds on disease control
Collaborator Contribution Access to novel therapeutic agents Funds to support clinical trials and to pay for access to clinical research data sets. Contributed to a value of up to £400,000.
Impact Activity and access to samples is part of ongoing discussion with the EMBER commercail consortia and the University Hospitals of Leicester
Start Year 2018
 
Description Development of Ang2-selective ligand-trap 
Organisation Inotrem SA
Country France 
Sector Private 
PI Contribution Development and validation of high affinity ligand trap system for human Ang2. Molecular 'know how' to test the affinity for mouse model being developed by Inotrem. Set up for the production of trap proteins for validation by Inotrem.
Collaborator Contribution Inotrem: Developed mouse model of sepsis, anti-sepsis small molecule. LifeArc: patent and commercailisation rights to Ang2 ligand trap system (joint owned with UoL).
Impact Biophysical screening for selectivity and affinity complete - Ang2 trap functional against mouse protein - can move towards mouse models. Licencing agreement with Inotrem. Patent approved: Publication number: WO2014096855 ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR; Patent granted in EU, US, AUS. This collaboration is ongoing and has been strengthened across two CiC awards. The relationship has just entered a more significant phase with focused delivery plans, for both parties, to move towards validation for sepsis.
Start Year 2018
 
Description Development of Ang2-selective ligand-trap 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Development and validation of high affinity ligand trap system for human Ang2. Molecular 'know how' to test the affinity for mouse model being developed by Inotrem. Set up for the production of trap proteins for validation by Inotrem.
Collaborator Contribution Inotrem: Developed mouse model of sepsis, anti-sepsis small molecule. LifeArc: patent and commercailisation rights to Ang2 ligand trap system (joint owned with UoL).
Impact Biophysical screening for selectivity and affinity complete - Ang2 trap functional against mouse protein - can move towards mouse models. Licencing agreement with Inotrem. Patent approved: Publication number: WO2014096855 ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR; Patent granted in EU, US, AUS. This collaboration is ongoing and has been strengthened across two CiC awards. The relationship has just entered a more significant phase with focused delivery plans, for both parties, to move towards validation for sepsis.
Start Year 2018
 
Description Development of a multi-marker assay of gut microbiome metabolites using targeted metabolomics as an outcome marker of cardio-metabolic disease 
Organisation Protexin
Country United Kingdom 
Sector Private 
PI Contribution Expertise in gut Metabolomics, cardio-metabolic diseases and biomarkers/ individual mass-spectrometry assays.
Collaborator Contribution provided technical guidance to develop a robust multi-marker assay, fit for its intended purpose. Now in the validation stage as a set of clincially relevent biomarkers.
Impact Received MRC P2D award (MC_PC_17194). The collaboration with Shimadzu Biotech, a world leading Japanese instrument company for mass spectrometry, has been key in the development of the method. Combined funding from the CiC and P2D funding streams have supported the growth of this relationship and enabled project staff to benefit from technical training and guidance at Shimadzu UK and follow on on-site (at UoL) from the company to successfully transfer the biomarker detection methodology across different LC-MS platforms. These data were the first outputs from the newly developed CLS multi-omics facility and have contributed to the national clinical/translational hub through the MRC National Phenome Centre Network. We now plan to implement the multi-marker assay for patient risk assessment in cardio-metabolic disease. Work ongoing and facility relocated to upgraded laboratories late 2020. Project reviewed March 2021.
Start Year 2018
 
Description Development of a multi-marker assay of gut microbiome metabolites using targeted metabolomics as an outcome marker of cardio-metabolic disease 
Organisation Shimadzu Corporation
Country Japan 
Sector Private 
PI Contribution Expertise in gut Metabolomics, cardio-metabolic diseases and biomarkers/ individual mass-spectrometry assays.
Collaborator Contribution provided technical guidance to develop a robust multi-marker assay, fit for its intended purpose. Now in the validation stage as a set of clincially relevent biomarkers.
Impact Received MRC P2D award (MC_PC_17194). The collaboration with Shimadzu Biotech, a world leading Japanese instrument company for mass spectrometry, has been key in the development of the method. Combined funding from the CiC and P2D funding streams have supported the growth of this relationship and enabled project staff to benefit from technical training and guidance at Shimadzu UK and follow on on-site (at UoL) from the company to successfully transfer the biomarker detection methodology across different LC-MS platforms. These data were the first outputs from the newly developed CLS multi-omics facility and have contributed to the national clinical/translational hub through the MRC National Phenome Centre Network. We now plan to implement the multi-marker assay for patient risk assessment in cardio-metabolic disease. Work ongoing and facility relocated to upgraded laboratories late 2020. Project reviewed March 2021.
Start Year 2018
 
Description Development of a multi-marker assay of gut microbiome metabolites using targeted metabolomics as an outcome marker of cardio-metabolic disease 
Organisation Waters Corporation
Department Waters Corporation
Country United Kingdom 
Sector Private 
PI Contribution Expertise in gut Metabolomics, cardio-metabolic diseases and biomarkers/ individual mass-spectrometry assays.
Collaborator Contribution provided technical guidance to develop a robust multi-marker assay, fit for its intended purpose. Now in the validation stage as a set of clincially relevent biomarkers.
Impact Received MRC P2D award (MC_PC_17194). The collaboration with Shimadzu Biotech, a world leading Japanese instrument company for mass spectrometry, has been key in the development of the method. Combined funding from the CiC and P2D funding streams have supported the growth of this relationship and enabled project staff to benefit from technical training and guidance at Shimadzu UK and follow on on-site (at UoL) from the company to successfully transfer the biomarker detection methodology across different LC-MS platforms. These data were the first outputs from the newly developed CLS multi-omics facility and have contributed to the national clinical/translational hub through the MRC National Phenome Centre Network. We now plan to implement the multi-marker assay for patient risk assessment in cardio-metabolic disease. Work ongoing and facility relocated to upgraded laboratories late 2020. Project reviewed March 2021.
Start Year 2018
 
Description Immunomodulation in the Lung by specific inhibition of the Sin3A/HDAC1 complex 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Experts in the analysis of HDAC in the epigenetic regulation of disease using molecular and structural biology approaches. Experts in smooth airway biology, asthma and COPD (cellular biology and haematological responses to therapeutics).
Collaborator Contribution LifeArc: Development of novel small molecule inhibitors for neglected disease of clear clinical need. Relationship with Asthma UK and interest in new therapeutics for asthma.
Impact The focus of this project involved the validation of the Sin3A protein as a therapeutic target for the treatment of asthma, and as a result, to work in collaboration with LifeArc and AZ to screen small molecule libraries. To date the validation has been unable to confirm linkage of Sin3A inhibition with the modulation of disease. This work is now supported by a joint iCase studentship with LifeArc (started in April 2019). Has applied to BBSRC (Q1 2020 - £710,000) for follow-up funding using constructs generated in this project. Updated Feb 2020.
Start Year 2017
 
Description Making age-adjusted normative data of the eye available in the ophthalmology clinic for the diagnosis of paediatric eye disease 
Organisation Translational Imaging Innovations
Country United States 
Sector Private 
PI Contribution The Ulverscroft Eye Unit (University Hospitals Leicester) and the research team has access to one of the world's largest OCT datasets from >1000 individuals from birth to adulthood, which can be used to develop approaches for childhood diagnosis. The aim is to make this technology accessible for the diagnosis of paediatric eye disease through the development of an age-adjusted normative OCT dataset for children (using historical data).
Collaborator Contribution TII: a US company expert in OCT software and device development and commercialization. TII have provided an in-kind contribution towards the development of a FDA approved dataset for use in clinical devices, by the pharmaceutical industry and the research community.
Impact Project outcome: the data will now be organised and processed and submitted to the FDA for approval. If achieved this dataset can then be incorporated in hand-held OCT devices for clinical applications in paediatric ophthalmology and for safety testing by the pharmaceutical industry for the development of new pharmacological treatments for children. In the meantime, work will continue with TII to further develop both the segmentation software and drive the next generation of handheld OTC equipment. These activities will generate novel shared IP and are likely to have significant impact on the global ophthalmic market. In addition, this methodology will be applied to develop new diagnostic methods for cerebral malaria in African paediatric patients. In combination with P2D funding (MC_PC_17194), discussions have taken place with segmentation software developers at the Iowa Institute for Biomedical imaging and developers of the next generation of hand-held OTC machines (LumoRes). doi: 10.1016/j.ophtha.2019.10.037
Start Year 2018
 
Description Novel expectorant sample processing accelerating development of face mask sampling and biomarker analysis 
Organisation QuantuMDx Group Ltd.
Country United Kingdom 
Sector Private 
PI Contribution Provide the UoL's Mask Aeorosol Sampling system (MASS) which has demonstrated potential to detect TB in patients who do not cough. Access to Cat III laboratory and patient samples.
Collaborator Contribution Expertise in the development of clinically relevant diagnostics for microbiological infections Provide the set-up to investigate the compatibility of solublised mask material with QuantuMDx CAPTURE-XT and Q-POC technology for bacterial concentration, lysis and DNA extraction with molecular detection of target pathogens, including TB bacteria. QuantuMDx will contribute staff time and provide access to their technology with full training.
Impact Outputs: Data suggested that UOL- MASS system is compatible with QuantuMDx - CaptureXT. Anticipated outputs from the project include: * Findings will support a Wellcome Trust Innovator Award application, to involve QuantuMDx for development of a front-end module to integrate MASS samples with Q-POC. * development of a novel end-to-end process for the non-invasive diagnostics for TB * publication of high impact papers Opportunity for commercial engagement for MRC CiC funding from MC-PC_16051
Start Year 2018
 
Description Novel kinase target in cancer therapy 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The aim of this agreement is to develop and use assays for kinase activity to screen an optimised kinase-focused compound collection provided through the AZ Open Innovation Scheme. Depending on the hit matter generated, the plan is to scale-up the established primary and secondary in vitro assays to screen additional targeted AZ compound sets and generate lead compounds, as well as establish cell lines to validate the hit compounds and undertake additional screens.
Collaborator Contribution AZ provides access through their Open Innovation scheme to ~50,000 pre-selected compounds. A more restricted kinase inhibitor set (KIL-set) of ~1,000 compounds will be provided to screen for inhibitors of the kinases studied and understand potential mechanisms of action of these inhibitors in cancer cells. AZ will evaluate hits identified from these screens to determine whether they are appropriate for further investment through computational biology and/or medicinal chemistry, or for limited testing in cell line panels.
Impact The project has used P2D funds (MC_PC_17194) to visit AZ to further screen AZ proprietary compounds using AZ in house high throughput systems. Project update February 2020: Industry-standard, activity-based biochemical screens have been completed. The SAR analysis of the hits has been discussed with AZ. Further collaboration with AZ for oncology drug development is postponed, awaiting for evidences for a link between NEK inhibitors and DNA damage response. Currently, a manuscript is in preparation to publish data package. The targeting of NEK8 is being de-prioritised (lack off suitable molecules and structural biology insights) the tool compounds and data produced to date will be used to write a publication for a high impact journals (within the next 6-8 months). Updated Feb 2020.
Start Year 2017
 
Description Phage Diagnostics for Lyme Diease 
Organisation Phelix Research & Development
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Expertise with the identification of bacteriophages PCR development skills towards developing a sensitive test using bacteria specific phages as a marker of Lyme disease.
Collaborator Contribution Phelix was set up with the aim of researching diagnostic techniques, prevention methods and, ultimately, treatment plans for chronic infectious diseases thought to be responsible for some of the main neurodegenerative and neurobehavioural conditions. Focus on supporting research surrounding bacteriophage viruses and their potential uses in chronic infection Access to Lyme Diease patient samples http://phelix.info/en/about/what-is-phelix/ RED Laboratoris (Belgium) - https://redlabs.be/ R.E.D. Laboratories is a private Belgian company, focused on developing and performing specialty research and diagnostic tests for chronic immune disorders, intestinal dysfunctions, tick-borne diseases (Lyme disease) and multifactorial disorders like autism and CFS. R.E.D laboratories provided expertise in the development of molecular diagnostic tests.
Impact Contracts in place, shared IP protection (patients in progress) and diagnostic methodology well developed. The validation of the test has been taken over by the R.E.D laboratories (Belgium). A licensing agreement was signed between Phelix and R.E.D Laboratories (2019). A commercial trial started on July 1st, 2019. The University team used P2D fund (MC_PC_17194) to go and visit R.E.D Laboratories in 2019. The University team gained valuable expertise in the development of molecular diagnostic tests. The visit marked also the start of a long-term collaboration between R.E.D and Leicester. Updated in Feb2020.
Start Year 2016
 
Description Phage Diagnostics for Lyme Diease 
Organisation R.E.D Laboratories
Country Belgium 
Sector Private 
PI Contribution Expertise with the identification of bacteriophages PCR development skills towards developing a sensitive test using bacteria specific phages as a marker of Lyme disease.
Collaborator Contribution Phelix was set up with the aim of researching diagnostic techniques, prevention methods and, ultimately, treatment plans for chronic infectious diseases thought to be responsible for some of the main neurodegenerative and neurobehavioural conditions. Focus on supporting research surrounding bacteriophage viruses and their potential uses in chronic infection Access to Lyme Diease patient samples http://phelix.info/en/about/what-is-phelix/ RED Laboratoris (Belgium) - https://redlabs.be/ R.E.D. Laboratories is a private Belgian company, focused on developing and performing specialty research and diagnostic tests for chronic immune disorders, intestinal dysfunctions, tick-borne diseases (Lyme disease) and multifactorial disorders like autism and CFS. R.E.D laboratories provided expertise in the development of molecular diagnostic tests.
Impact Contracts in place, shared IP protection (patients in progress) and diagnostic methodology well developed. The validation of the test has been taken over by the R.E.D laboratories (Belgium). A licensing agreement was signed between Phelix and R.E.D Laboratories (2019). A commercial trial started on July 1st, 2019. The University team used P2D fund (MC_PC_17194) to go and visit R.E.D Laboratories in 2019. The University team gained valuable expertise in the development of molecular diagnostic tests. The visit marked also the start of a long-term collaboration between R.E.D and Leicester. Updated in Feb2020.
Start Year 2016
 
Description Specific NOX4 inhibitors as novel therapeutics for lung disease 
Organisation Fibronox
Country United States 
Sector Private 
PI Contribution Expertise in NOX4 expression, biophysical/structural biology, and cell-based models to create a pipeline of scalable, direct NOX4 binding studies for optimisation of drug properties, and subsequent validation as potential novel therapeutics in asthma and other respiratory diseases.
Collaborator Contribution Provide access to molecule (as in kind contribution)
Impact Work with the Fibronox molecule will provide proof of concept for the druggabilty of NOX4 and enable to development of assays for the biophysical and cellular proliferating of novel NOX4 specific small molecules.
Start Year 2018
 
Description Targeting proline biosynthesis for cancer therapy 
Organisation Beatson Institute for Cancer Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Access to a dedicated LD3 staff member to establish a key enzymatic assay to validate small molecules generated through the collaboration between CRUK accelerator and the Beatson Institute for Cancer Research.
Collaborator Contribution Access to individuals with knowledge and experience of undertaking biophysical target validation. Expertise in cancer drug development and the screening and optimisation of small fragment library.
Impact CRUK Accelerator funding awarded in March 2019. Key enzymatic assay established. Preliminary fragment based screening has taken place and validation screening has begun.
Start Year 2018
 
Description Targeting proline biosynthesis for cancer therapy 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Access to a dedicated LD3 staff member to establish a key enzymatic assay to validate small molecules generated through the collaboration between CRUK accelerator and the Beatson Institute for Cancer Research.
Collaborator Contribution Access to individuals with knowledge and experience of undertaking biophysical target validation. Expertise in cancer drug development and the screening and optimisation of small fragment library.
Impact CRUK Accelerator funding awarded in March 2019. Key enzymatic assay established. Preliminary fragment based screening has taken place and validation screening has begun.
Start Year 2018
 
Title ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR 
Description In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided. 
IP Reference US2015322414 
Protection Patent granted
Year Protection Granted 2015
Licensed Yes
Impact work with Inotrem and LifeArc is ongoing to use the ligand trap as part of a pre-clincal model in the development of novel therapeutics to treat sepsis
 
Title ECG EVALUATION 
Description A method for assessing the electrical function of a heart, a method for determining a subject's need for the implantation of an implantable cardioverter defibrillator or the need for administration of an anti-arrhythmic agent, and apparatus for assessing the function of the heart and a computer program product. The methods and products involve analysis of ECG. 
IP Reference WO2015150831 
Protection Patent granted
Year Protection Granted 2015
Licensed No
Impact As described in the Collaborations and Partnerships section. To be granted in Australia and USA, in national phase in 5 countries.
 
Title METHOD AND APPARATUS FOR EVALUATING CARDIAC FUNCTION 
Description The present invention relates to a method for assessing the electrical function of a heart, comprising the steps of:- (1) for each of a plurality of leads of an ECG, determining a value derived from the output of that lead and which corresponds to an action potential duration; (2) for each of the plurality of leads of the ECG, determining a value derived from the output of that lead and which corresponds to a diastolic interval; (3) for each of the plurality of leads of the ECG, determining a relationship between the determined values for action potential duration and for diastolic interval; (3) assessing the differences between the determined relationships for each of the plurality of leads. The invention further relates to apparatus and a computer program that may be used in the method. 
IP Reference WO2011117608 
Protection Patent granted
Year Protection Granted 2011
Licensed No
Impact As described in the Collaboration and Partnerships section of this form. Has recently been granted in USA (13/3/2018) and Australia (9/4/2018) in addition to China (2015) and Japan (2015) and is under review in Canada, Europe, and India.
 
Title PHAGE-BASED DETECTION OF BORRELIOSIS AND MEANS THEREFOR 
Description This invention relates to methods of detecting Borrelia burgdorferi sensu lato or for detecting Borrelia associated with Relapsing Fever (RF), kits for carrying out such methods, and methods of treating Borrelia burgdorferi sensu lato or RF infections in a subject. Uses of phage specific for Borrelia are also provided. 
IP Reference WO2018083491 
Protection Patent granted
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Described else where - see Collaborations section for details
 
Title A near patient paracetamol test 
Description Development of a novel detection system suitable for near patient measurement of paracetamol. 
Type Of Technology Detection Devices 
Year Produced 2019 
Impact Next phase is further development of a device format suitable to be tested in a future MRC DPFS funded project. This device will address the need for a rapid, near patient test for circulating levels of paracetamol in blood to enable early detection of overdoses, improve patient outcomes and reduce time in the Emergency Department. 
 
Title A new software for the isolation of the neural activity from recordings with electrodes in the brain. 
Description A portable device and tracking software algorithm for the isolation of the neural activity from recordings with electrodes in the brain. 
Type Of Technology Software 
Year Produced 2018 
Impact It is still too early to assess the impact of the new software 
 
Title Brain TV - modelling software 
Description Pulsation signal analysis and modelling software. 
Type Of Technology Software 
Year Produced 2019 
Impact Brain TV correctly excluded patients with no major brain injury, with the exception of one patient with a 5 mm mid-line shift whose brain tissue pulsations were correctly identified by as abnormal. This case was presented as a poster at the London Trauma conference in December 2019. 
 
Title LD3 project - Bacterial aerosol sampling device (MASS) 
Description Development of a bacterial aerosol sampling device which is compatible with routine clinical practice. To provide a simple, cheap and effective test which enables rapid detection of respiratory pathogens and early use of targeted antimicrobials. See https://www.youtube.com/watch?v=4nq3y0P6t44 for a public health video explaining how the mask works 
Type Of Technology Systems, Materials & Instrumental Engineering 
Year Produced 2018 
Impact None to date. 
URL https://le.ac.uk/news/2020/february/19-tb-masks
 
Title LD3 project - Breath sampler for clinical diagnostics and stratified medicine 
Description Improving on a current device by designing and developing a higher performing diagnostic breath sampling device that is smaller, non-invasive and cost effective which will deliver both a fast and accurate diagnosis of acute breathless patients with respiratory diseases such as asthma, pneumonia, COPD and heart failure. 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2018 
Impact None to date. 
 
Title The Fail-safe Interatrial Shunt Device 
Description The Fail-safe Interatrial Shunt Device enables left atrial depressurisation via a left atrial pressure responsive reversible interatrial shunt to prevent decompensation leading to acute heart failure. 
Type Of Technology Detection Devices 
Year Produced 2020 
Impact This approach promises to substantially reduce health care costs by further reducing acute heart failure admissions and eliminating the need for a dedicated team to monitor and respond to changes in pulmonary artery pressure signals. 
 
Description Bacteriophages as diagnostic markers and therapeutic agents for predicting and treating Lyme disease - Invitation to give a talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Dr J.S who received two rounds of LD3/ MRC CiC awards (MC_PC_15045 and MC_PC_17171) to develop a PCR-based test to diagnose Lyme disease got invited to give a talk at the international Crypto-Infection Conference, Dublin, Ireland, on June 2019 . Presentation title: "Bacteriophages as diagnostic markers and therapeutic agents for predicting and treating Lyme disease".
Year(s) Of Engagement Activity 2019
 
Description Invited Speaker - Hernan Rey: "How do we pick the right spike sorting approach for a given application?" 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Dr Hernan Rey invited to present on the subject of "How do we pick the right spike sorting approach for a given application?" as it relates to automated capture and analysis of EEG signals.

Conference - Spike Sorting and Reproducibility for Next Generation Electrophysiology 24. and 25. June 2019 Informatics Forum, University of Edinburgh
Year(s) Of Engagement Activity 2019
URL http://workshops.inf.ed.ac.uk/ssnge/